BIOMAT Database Logo BIOMAT Database Logo

A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. 1995

R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
AIDS Center, St Vincent's Hospital and Medical Center of New York, NY 10011, USA.

Three nucleoside analogues, zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), are approved for use in the treatment of patients with HIV infection. This retrospective study compares the 3 drugs and examines the overall utility of antiretroviral therapy by way of comparisons to a no treatment (No Rx) group in patients with advanced HIV disease. Patients with advanced HIV disease were enrolled in didanosine (August 1989-December 1990) or zalcitabine (October 1990-February 1992) expanded access programmes; continued on zidovudine treatment despite fulfilling criteria for zidovudine failure or intolerance; or maintained on no antiretroviral treatment. Statistical analysis revealed that patients on nucleoside analogue therapy had fewer opportunistic infections (P = 0.001) than those who received no antiretroviral treatment. The Kaplan-Meier 12-month estimate of survival was significantly longer among patients who switched from zidovudine to zalcitabine but not among patients who switched to didanosine, when compared to the other 2 groups (P = 0.05).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
November 2000, AIDS (London, England),
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
May 1993, Annals of internal medicine,
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Studies of zidovudine in combination with didanosine and zalcitabine.
January 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
September 2000, AIDS research and human retroviruses,
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Didanosine for zidovudine-intolerant patients with HIV disease.
November 1992, Lancet (London, England),
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
April 1996, Antiviral therapy,
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
November 1993, Lancet (London, England),
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
January 1995, Annals of internal medicine,
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
February 2004, Hepatology (Baltimore, Md.),
R A Torres, and M R Barr, and K I McIntyre, and J R Thornton, and W M Shay, and R D Feldman, and N J George, and D J Britton
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
May 1995, Archives of internal medicine,
Copied contents to your clipboard!